

APPLERA CORP
Form 4
November 21, 2006

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
DEBLASI UGO D

(Last) (First) (Middle)

APPLERA CORPORATION, 301 MERRITT 7

(Street)

NORWALK, CT 06851-1070

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
APPLERA CORP [ABI/CRA]

3. Date of Earliest Transaction
(Month/Day/Year)
11/21/2006

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

____ Director _____ 10% Owner
 Officer (give title below) _____ Other (specify below)
Vice President and Controller

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
____ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Code | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |
|---------------------------------------|--------------------------------------|--|---------|---|---|--|-----------------------------------|
| | | | Code | V | Amount | (D) | Price |
| Applied Biosystems Group Common Stock | 11/21/2006 | | S | | 2,000 | D | \$ 36.68 2,958.9205 |
| Applied Biosystems Group Common Stock | 11/21/2006 | | S | | 692 | D | \$ 36.7 2,266.9205 |
| Celera Genomics | 11/21/2006 | | M | | 1,150 | A | \$ 8.56 2,025.5842 |

Edgar Filing: APPLERA CORP - Form 4

Group
Common
Stock

Celera
Genomics

| | | | | | | | |
|--------------------------|------------|---|-----|---|-------------|------------|---|
| Group Common Stock | 11/21/2006 | S | 100 | D | \$ 14.23 | 1,925.5842 | D |
|--------------------------|------------|---|-----|---|-------------|------------|---|

Celera
Genomics

| | | | | | | | |
|--------------------------|------------|---|-----|---|-------------|------------|---|
| Group Common Stock | 11/21/2006 | S | 500 | D | \$ 14.24 | 1,425.5842 | D |
|--------------------------|------------|---|-----|---|-------------|------------|---|

Celera
Genomics

| | | | | | | | |
|--------------------------|------------|---|-----|---|-------------|----------|---|
| Group Common Stock | 11/21/2006 | S | 550 | D | \$ 14.25 | 875.5842 | D |
|--------------------------|------------|---|-----|---|-------------|----------|---|

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Security (Instr. 3 and 4) |
|---|--|--------------------------------------|--|--------------------------------|---|--|---|
| Celera Genomics Group Employee Stock Options-Right to Buy | \$ 8.56 | 11/21/2006 | | M | 1,150 | 01/21/2003 01/21/2009 | Celera Genomics Group Common Stock |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|---|---------------|-----------|-------------------------------|-------|
| | Director | 10% Owner | Officer | Other |
| DEBLASI UGO D APPLERA CORPORATION 301 MERRITT 7 NORWALK, CT 06851-1070 | | | Vice President and Controller | |

Signatures

| | |
|--|---------------------|
| /s/ Thomas P. Livingston, Attorney-In-Fact for Ugo D. DeBlasi | 11/21/2006 |
| <small>**Signature of Reporting Person</small> | <small>Date</small> |

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.